Page 1

ASX Announcement IMUGENE Quarterly Activities and Cash Flow Report Quarter ended 30 June 2021 SYDNEY , Australia , 23 July 2021 : Imugene Limited ( ASX : IMU ) , a clinical stage immuno - oncology company , is pleased to announce its Quarterly Cash Flow report ( Appendix 4C ) for the quarter ended 30 June 2021 . Key highlights this quarter include : • $ 29.5m cash balance as at 30 June 2021 . Quarterly research and development expenditure was $ 3.6m Highest dose cohort in Phase 1 clinical trial of PD1 - Vaxx reached • HER - Vaxx presented at AACR 2021 meeting • CF33 CHECKVacc presented at AACR 2021 meeting • Prestigious Clinical Cancer Research Journal Publishes HER - Vaxx Phase 1 Data • Worldwide license of CF33 CD19 ( onCARlytics ) for the treatment of solid tumours • Appointment of Dr. Monil Shah as Chief Business Officer • HER - Vaxx presented at the ESMO World Congress on Gastrointestinal Cancer 2021 Annual Meeting • CHECKVacc received FDA IND clearance Update on Clinical Trials HER - Vaxx Following completion of recruitment of the Phase 2 trial in January 2021 , Imugene's Chief Medical Officer Dr Rita Laeufle was able to present on the HER - Vaxx cancer immunotherapy program at the American Association for Cancer Research ( AACR ) 2021 Annual Meeting in April . On 2nd of July , 2021 HER - Vaxx data was presented at the ESMO World Congress on Gastrointestinal Cancer 2021 Annual Meeting . The abstract presentation was entitled ' HERIZON : A PHASE 1B / 2 OPEN - LABEL STUDY OF IMU - 131 HER2 / NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY WITH RANDOMIZATION IN PHASE 2 IN PATIENTS WITH HER2 / NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION ' Updated Interim Analysis Results The presentation expanded on previously presented interim analysis data presented at AACR2021 . The ESMO presentation highlights and presents the following new data : • • HER - Vaxx treatment resulted in a 50 % Overall Response Rate ( ORR ) compared to 29 % in patients treated with chemotherapy alone . The ORR measures the percentage of patients who responded to treatment with a partial response ( PR ) or better . Treatment with HER - Vaxx clearly demonstrates patients develop high levels of HER2 - specific antibodies early in the treatment protocol and are maintained during treatment and maintenance phase with only a few booster injections . IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com